PURPOSE: Pulmonary vein isolation (PVI) during ablation of atrial fibrillation (AF) is associated with pulmonary vein stenosis (PVS). Although the reported incidence of PVS has fallen in recent years, the precise rate of PVS is unknown. Coherent guidelines for screening and treatment of PVS are not established. We reviewed literature to investigate the incidence, diagnosis, and management of PVS as a complication of PVI. METHODS: We reviewed 41 manuscripts that described a total of 4,615 subjects (median, 84 subjects/study). RESULTS: The incidence of PVS after PVI reported in literature from 1999 to 2004 ranges from 0 to 44% (mean, 6.3%; median, 5.4%), whereas studies after 2004 report an incidence of 0-19% (mean, 2%; median, 3.1%; p < 0.001). PVS symptoms typically occur with reduction of lung perfusion by 20-25%. Variable criteria exist for diagnosis of PVS by magnetic resonance imaging, computed tomography, and perfusion imaging. The restenosis rate for treatment with balloon angioplasty ranges from 30 to 87% (mean, 60%; median, 47%), compared with immediate stenting that ranges from 14 to 57% (mean, 34%; median, 33%). CONCLUSIONS: Recent peer-reviewed articles suggest that PVI carries a 3-8% risk of developing PVS, but they likely underestimate the incidence of PVS, as specific screening and diagnostic guidelines are not established. Imaging modalities should be used to screen patients after ablation of AF since early recognition of PVS improves treatment outcomes. Treatment with angioplasty and stent placement can improve symptoms and lung perfusion but the benefit of treatment with immediate stent placement remains controversial. It is critical to maintain a high clinical index of suspicion for PVS in at-risk individuals to ensure timely detection and treatment.
PURPOSE: Pulmonary vein isolation (PVI) during ablation of atrial fibrillation (AF) is associated with pulmonary vein stenosis (PVS). Although the reported incidence of PVS has fallen in recent years, the precise rate of PVS is unknown. Coherent guidelines for screening and treatment of PVS are not established. We reviewed literature to investigate the incidence, diagnosis, and management of PVS as a complication of PVI. METHODS: We reviewed 41 manuscripts that described a total of 4,615 subjects (median, 84 subjects/study). RESULTS: The incidence of PVS after PVI reported in literature from 1999 to 2004 ranges from 0 to 44% (mean, 6.3%; median, 5.4%), whereas studies after 2004 report an incidence of 0-19% (mean, 2%; median, 3.1%; p < 0.001). PVS symptoms typically occur with reduction of lung perfusion by 20-25%. Variable criteria exist for diagnosis of PVS by magnetic resonance imaging, computed tomography, and perfusion imaging. The restenosis rate for treatment with balloon angioplasty ranges from 30 to 87% (mean, 60%; median, 47%), compared with immediate stenting that ranges from 14 to 57% (mean, 34%; median, 33%). CONCLUSIONS: Recent peer-reviewed articles suggest that PVI carries a 3-8% risk of developing PVS, but they likely underestimate the incidence of PVS, as specific screening and diagnostic guidelines are not established. Imaging modalities should be used to screen patients after ablation of AF since early recognition of PVS improves treatment outcomes. Treatment with angioplasty and stent placement can improve symptoms and lung perfusion but the benefit of treatment with immediate stent placement remains controversial. It is critical to maintain a high clinical index of suspicion for PVS in at-risk individuals to ensure timely detection and treatment.
Authors: Eduardo B Saad; Antonio Rossillo; Cynthia P Saad; David O Martin; Mandeep Bhargava; Demet Erciyes; Dianna Bash; Michelle Williams-Andrews; Salwa Beheiry; Nassir F Marrouche; James Adams; Ennio Pisanò; Raffaele Fanelli; Domenico Potenza; Antonio Raviele; Aldo Bonso; Sakis Themistoclakis; Joannes Brachmann; Walid I Saliba; Robert A Schweikert; Andrea Natale Journal: Circulation Date: 2003-11-17 Impact factor: 29.690
Authors: Geoffrey Lee; Paul B Sparks; Joseph B Morton; Peter M Kistler; Jitendra K Vohra; Caroline Medi; Raphael Rosso; Andrew Teh; Karen Halloran; Jonathan M Kalman Journal: J Cardiovasc Electrophysiol Date: 2010-08-19
Authors: Hakan Oral; Bradley P Knight; Hiroshi Tada; Mehmet Ozaydin; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Christof Burgstahler; Tobias Trabold; Axel Kuettner; Andreas F Kopp; Christian Mewis; Volker Kuehlkamp; Claus D Claussen; Stephen Schroeder Journal: Int J Cardiol Date: 2005-07-10 Impact factor: 4.164
Authors: Athar M Qureshi; Lourdes R Prieto; Larry A Latson; Geoffrey K Lane; C Igor Mesia; Penelope Radvansky; Richard D White; Nassir F Marrouche; Eduardo B Saad; Dianna L Bash; Andrea Natale; John F Rhodes Journal: Circulation Date: 2003-09-02 Impact factor: 29.690
Authors: Pablo Pazos-López; Cristina García-Rodríguez; Alba Guitián-González; Emilio Paredes-Galán; María Ángel De La Guarda Álvarez-Moure; Marta Rodríguez-Álvarez; José Antonio Baz-Alonso; Elvis Teijeira-Fernández; Francisco Eugenio Calvo-Iglesias; Andrés Íñiguez-Romo Journal: World J Cardiol Date: 2016-01-26
Authors: Faisal M Merchant; Mathew R Levy; Shahriar Iravanian; Ramal M Weragoda; Edward C Clermont; Heval M Kelli; Robert L Eisner; David Vadnais; Mikhael F El-Chami; Angel R Leon; David B Delurgio Journal: J Atr Fibrillation Date: 2016-08-31